EMPOWER
Transform drug discovery and materials research with advanced molecular modeling.
Traditional pharma approaches to drug discovery synthesize ~1,000 compounds a year.
Our physics-based platform evaluates billions of molecules per week with a high degree of accuracy.
Our approach enables discovery of high-quality, novel molecules more rapidly, at lower cost, and we believe with a higher likelihood of success compared to traditional methods.
OUR PLATFORM OPENS NEW WORLDS OF POSSIBILITY.
Find the solutions you’re looking for:
DRUG DISCOVERY
Comprehensive solutions to accelerate lead discovery and optimization, validated by our collaborators' success across a wide array of targets.
MATERIALS SCIENCE
Molecular simulations of chemical systems to design materials essential to modern life.
SOLUTION SPOTLIGHT:
LIVEDESIGN
LiveDesign, a linchpin of our platform, enables interactive and collaborative molecule design, aggregation and sharing of data, and end-to-end discovery project coordination between chemists, modelers, and biologists. Learn more about our user-friendly enterprise informatics solution.
REQUEST INFO
Our platform is used by industry leaders globally. See how our physics-based methods can help you open new worlds of possibility.
ACADEMIC LICENSING
We support the next generation of scientists through special licensing for academic institutions.
Small Molecule Drug Discovery Products
Biologics Drug Discovery Products
Materials Science Products
THE POWER OF THE SCHRÖDINGER PLATFORM
The power of our platform can be seen in a case study published in 2017 in the Journal of Medicinal Chemistry.
Researchers compared the effectiveness of four approaches to identify the 10 compounds most likely to yield tight binding with a target protein: selection by a medicinal chemist, manual modeling, docking followed by manual filtering, and free energy calculations (FEP) using the Schrödinger platform. Researchers then synthesized the molecules recommended by each approach.
The Schrödinger FEP approach outperformed the others; 80 percent of its recommended molecules demonstrated improved affinity, compared with 10 percent of molecules suggested by the other approaches.